EMEA-002763-PIP01-20
Key facts
| Active substance |
(R)-2-(1-(6-Amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (DAY101)
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0500/2020
|
| PIP number |
EMEA-002763-PIP01-20
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of paediatric low grade glioma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Day One Biopharmaceuticals, Inc
Email: davy.chiodin@dayonebio.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|